uniQure Stock Jumps as FDA Clears Faster Path for Its Huntington’s Gene Therapy

uniQure N.V. (NASDAQ: QURE) is rallying after the U.S. Food and Drug Administration agreed to an accelerated‑approval pathway for its Huntington’s disease gene therapy, AMT‑130, based on existing phase 1/2 data. This reverses earlier, more cautious feedback and puts a near‑term Biologics License Application (BLA) back on the table, which investors see as a major de‑risking event.

 What the FDA is allowing

The FDA has told uniQure it can file a BLA for AMT‑130 for Huntington’s disease using three‑year data from its ongoing phase 1/2 study as the main evidence package for accelerated approval. That means the company can move ahead with a filing rather than waiting for a large, traditional phase 3 trial to read out.

Earlier in the year, the agency had pushed back on this plan and signaled that phase 1/2 data plus external controls would likely be insufficient, which led many investors to assume a long delay. With this latest update, uniQure now plans to submit the BLA in the near term while working with the FDA on a required confirmatory trial using a more conventional, concurrently controlled design.

 Why this matters for QURE

For uniQure and its shareholders, the decision resurrects the possibility of AMT‑130 becoming the first approved genetic treatment for Huntington’s disease, a fatal neurodegenerative condition with no disease‑modifying therapies today. Bringing back an accelerated‑approval path:

• Pulls expected timelines for a potential U.S. launch closer.
• Increases the perceived probability that AMT‑130 can generate future revenue.
• Signals that regulators see the phase 1/2 data as strong enough to warrant a formal review.

Because the stock had previously sold off on concerns about a tougher regulatory stance, this “U‑turn” from the FDA has triggered a sharp relief rally in QURE as the market reprices both risk and opportunity.